| TN1923 |
Mesaconine
|
6792-09-2
|
98%
|
|
|
Mesaconine is an ingredient from Aconitum carmichaelii Debx.. Mesaconine has a cardiac effect and anti-NF-κB activity. Mesaconine may be part of the material bas...
|
| T9962 |
Mepolizumab
|
196078-29-2
|
98%
|
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody neutralizing IL-5. Mepolizumab can be used in studies about severe eosinophilic asthma and eosinophili...
|
| TN1013 |
Cucurbitacin D
|
3877-86-9
|
98%
|
|
|
Cucurbitacin D has anticancer effects, it induces apoptosis through caspase-3 and phosphorylation of JNK in hepatocellular carcinoma cells.
|
| T2S1040 |
Jolkinolide B
|
37905-08-1
|
98%
|
|
|
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud. Jolkinolide B induces apoptosis in cancer cells. Jolkinolide B can...
|
| T1813 |
VGX-1027
|
6501-72-0
|
98%
|
|
|
VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties.
|
| T10497 |
Benralizumab
|
1044511-01-4
|
98%
|
|
|
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, ...
|
| T77426 |
Pascolizumab
|
331243-22-2
|
98%
|
Pascolizumab
|
|
Pascolizumab (SB-240683) is a humanized monoclonal antibody against IL-4. Pascolizumab has asthmatic effects and can be used to study allergic rhinitis.
|
| T76978 |
Siltuximab
|
541502-14-1
|
98%
|
Siltuximab
|
|
Siltuximab（CNTO-328） is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.
|
| T76896 |
Abrezekimab
|
2043952-59-4
|
98%
|
Abrezekimab
|
|
Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13. Abrezekimab inhibits binding t...
|
| T76892 |
Ordesekimab
|
879293-15-9
|
98%
|
Ordesekimab
|
|
Ordesekimab (AMG 714) is a human IgG1 κ-anti-IL-15 (Interleukin Related) monoclonal antibody. Ordesekimab binds competitively to IL-15, inhibiting the interactio...
|
| T76884 |
Spesolimab
|
2097104-58-8
|
98%
|
Spesolimab
|
|
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. IL-36 plays an important role in the immune system and is associated with a reduction in biom...
|
| T76873 |
Nidanilimab
|
2171061-85-9
|
98%
|
Nidanilimab
|
|
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. Nidanilimab has antitumor activity, cutting off the IL1α and IL1β...
|
| T76784 |
Tildrakizumab
|
1326244-10-3
|
98%
|
Tildrakizumab
|
|
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody against IL-23 (p19 subunit). Tildrakizumab targets single-stranded IL-23 with a Kd value of ...
|
| T76779 |
Brodalumab
|
1174395-19-7
|
98%
|
|
|
Brodalumab (AMG 827) is a human monoclonal antibody targeting interleukin 17 receptor (IL-17R) IgG2, often used as an immunosuppressant in the treatment of psori...
|
| T76778 |
Risankizumab
|
1612838-76-2
|
98%
|
|
|
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. Risankizumab inhibits IL-17 production induced by hu...
|
| T76777 |
Bermekimab
|
1401965-15-8
|
98%
|
|
|
Bermekimab (MABp1) is a humanized monoclonal antibody against interleukin-1α (IL-1α).Bermekimab has potential anti-inflammatory activity to prevent skin inflamma...
|
| T76773 |
Rolinsatamab
|
2095467-30-2
|
98%
|
Rolinsatamab
|
|
Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequenc...
|
| T76744 |
Enokizumab
|
909875-08-7
|
98%
|
Enokizumab
|
|
Enokizumab (MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.
|
| T76722 |
Sarilumab
|
1189541-98-7
|
98%
|
|
|
Sarilumab （SAR-153191）is a potent interleukin-6 IL-6 receptor antagonist and a human immunoglobulin G1 monoclonal antibody. Sarilumab inhibits IL-6-mediated sign...
|
| T76704 |
Tralokinumab
|
1044515-88-9
|
98%
|
Tralokinumab
|
|
Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 r...
|
